The most recent study involved DNA-based vaccines (pDom-M/F) targeting MAGED4B and FJX1 (two TAAs), which were expressed at higher levels in HNSCC tumor samples than in normal tissue. The gene discussed is MAGED4B; the disease is head and neck squamous cell carcinoma.